Trial intelligence / Profile preview

MAHOGANY: zanubrutinib-based combinations versus lenalidomide + rituximab in relapsed or refractory follicular lymphoma or marginal zone lymphoma

MOH_2023-08-06_012863Phase 3Recruiting

Sponsor

BeOne Medicines

Start

Jul 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1